Stock Track | Hims & Hers Health Soars 6.22% Intraday on J.P. Morgan's Bullish Initiation and GLP-1 Drug Launch

Stock Track04-24

Hims & Hers Health Inc. (HIMS) experienced a significant intraday surge of 6.22% on Friday, as the stock opened sharply higher.

The rally was primarily driven by J.P. Morgan initiating coverage on the telehealth company with an "overweight" rating and a $35 price target. Analysts highlighted the potential for the Novo partnership to remove legal overhang and position the firm as a comprehensive platform. They also noted the company's weight loss specialty could grow further this year, supported by a more stable GLP-1 business, potential peptide legalization, and expected revenue reacceleration in the second half.

Adding to the positive sentiment, the company's platform has fully launched multiple FDA-certified GLP-1 drugs, including Eli Lilly's Zepbound. Furthermore, a potential regulatory shift by the U.S. FDA to relax restrictions on peptide injectable drugs could open new revenue streams for the digital health platform, which boasts over 2.5 million subscribers.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1153887516?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-24 21:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1153887516","market":"us","top_or_hot":-1,"title":"Stock Track | Hims & Hers Health Soars 6.22% Intraday on J.P. Morgan's Bullish Initiation and GLP-1 Drug Launch","media":"Stock Track","content":"<p>Hims & Hers Health Inc. (HIMS) experienced a significant intraday surge of 6.22% on Friday, as the stock opened sharply higher.</p><p>The rally was primarily driven by J.P. Morgan initiating coverage on the telehealth company with an \"overweight\" rating and a $35 price target. Analysts highlighted the potential for the Novo partnership to remove legal overhang and position the firm as a comprehensive platform. They also noted the company's weight loss specialty could grow further this year, supported by a more stable GLP-1 business, potential peptide legalization, and expected revenue reacceleration in the second half.</p><p>Adding to the positive sentiment, the company's platform has fully launched multiple FDA-certified GLP-1 drugs, including Eli Lilly's Zepbound. Furthermore, a potential regulatory shift by the U.S. FDA to relax restrictions on peptide injectable drugs could open new revenue streams for the digital health platform, which boasts over 2.5 million subscribers.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Hims & Hers Health Soars 6.22% Intraday on J.P. Morgan's Bullish Initiation and GLP-1 Drug Launch</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Hims & Hers Health Soars 6.22% Intraday on J.P. Morgan's Bullish Initiation and GLP-1 Drug Launch\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-04-24 21:39</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Hims & Hers Health Inc. (HIMS) experienced a significant intraday surge of 6.22% on Friday, as the stock opened sharply higher.</p><p>The rally was primarily driven by J.P. Morgan initiating coverage on the telehealth company with an \"overweight\" rating and a $35 price target. Analysts highlighted the potential for the Novo partnership to remove legal overhang and position the firm as a comprehensive platform. They also noted the company's weight loss specialty could grow further this year, supported by a more stable GLP-1 business, potential peptide legalization, and expected revenue reacceleration in the second half.</p><p>Adding to the positive sentiment, the company's platform has fully launched multiple FDA-certified GLP-1 drugs, including Eli Lilly's Zepbound. Furthermore, a potential regulatory shift by the U.S. FDA to relax restrictions on peptide injectable drugs could open new revenue streams for the digital health platform, which boasts over 2.5 million subscribers.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HIMS","symbol_name":"Hims & Hers Health Inc.","start_time":0,"source_url":"","article_id":"1153887516","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1153887516","pubTimestamp":1777037981,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Hims & Hers Health Inc. (HIMS) experienced a significant intraday surge of 6.22% on Friday, as the stock opened sharply higher.The rally was primarily driven by J.P. Morgan initiating coverage on the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HIMS":"Hims & Hers Health Inc."},"translate_title":"个股追踪|摩根大通看涨启动和GLP-1药物上市Hims&Hers Health盘中大涨6.22%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HIMS":1},"content_text":"Hims & Hers Health Inc. (HIMS) experienced a significant intraday surge of 6.22% on Friday, as the stock opened sharply higher.The rally was primarily driven by J.P. Morgan initiating coverage on the telehealth company with an \"overweight\" rating and a $35 price target. Analysts highlighted the potential for the Novo partnership to remove legal overhang and position the firm as a comprehensive platform. They also noted the company's weight loss specialty could grow further this year, supported by a more stable GLP-1 business, potential peptide legalization, and expected revenue reacceleration in the second half.Adding to the positive sentiment, the company's platform has fully launched multiple FDA-certified GLP-1 drugs, including Eli Lilly's Zepbound. Furthermore, a potential regulatory shift by the U.S. FDA to relax restrictions on peptide injectable drugs could open new revenue streams for the digital health platform, which boasts over 2.5 million subscribers.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1153887516","isCrawlerRequest":true}